Yonjin Venture

TECLens, LLC is a development stage company based in St. James, New York, focused on designing and manufacturing medical contact lenses for myopia treatment. Established in 2013, the company has developed a non-invasive therapy involving the use of its product, the CXLens (Corneal Crosslinking Lens), which is worn for just half an hour in a doctor's office. This innovative lens features real-time ultrasound sensing and a high oxygen concentration environment to ensure precise targeting and stability during treatment. TECLens aims to address various vision issues, including progressive myopia in children and vision problems in adults, such as hyperopia and low-order myopia. Its technology is designed to improve patients' eye health and potentially reduce the long-term risks associated with traditional corrective lenses.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Intressa Vascular focuses on developing innovative solutions for cardiovascular conditions, particularly addressing aortic dissection. The company utilizes a proprietary braiding technology platform to create multilayer stents designed for next-generation endovascular treatments. These products assist physicians in effectively managing the serious impacts of aortic dissections, ultimately aiming to enhance patient outcomes while minimizing the risk of ischemic complications. By fostering a collaborative and constructive approach, Intressa Vascular is committed to advancing patient care through high-quality medical products.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

Shenzhen Anteland Technology Co., Ltd, founded in 2015, specializes in the research and development, manufacturing, and sales of laser direct imaging equipment. The company has made significant strides in micro and submicron lithography technology, achieving advanced capabilities both domestically and internationally. Anteland is recognized as a leader in DFAI technology, which is utilized in maskless micro and submicron lithography. Its product offerings include laser exposure machines that cater to various industries such as textile, decal, label printing, package printing, glass, semiconductor, and photovoltaic sectors. These machines feature diverse exposure areas, light sources, and laser modules, delivering high precision and power to meet the needs of its customers.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates that target and eliminate disease-causing proteins, primarily for the treatment of cancer and neurodegenerative disorders. The company's lead product candidate, CFT7455, is an orally bioavailable degrader designed to target IKZF1/3 for multiple myeloma and other lymphomas. Additionally, C4 is advancing CFT8634, which targets BRD9 for specific solid tumors, alongside programs aimed at genetically defined resistant solid tumors. C4 Therapeutics utilizes its proprietary Degronimid platform, which allows for the selective degradation of proteins through the natural ubiquitin/proteasome system, potentially addressing previously undruggable targets while minimizing drug resistance. The company has formed strategic collaborations with major industry players, and it aims to make a significant impact on the treatment landscape through its advanced protein degradation science and multiple development programs. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics continues to innovate in the field of targeted therapy.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Decipher Biosciences, Inc. is a genomic information company focused on developing and commercializing clinical tests for urologic cancers. The company offers the Decipher Prostate Biopsy test, which analyzes tumor tissue to help determine appropriate treatment based on the tumor's metastatic potential. Additionally, it provides the Decipher Bladder test, a genomic subtyping tool that classifies muscle-invasive bladder cancer and identifies patients who may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences has a research and development center in Vancouver, Canada. The company is also building the GRID database, which contains over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to discover biomarkers that indicate responses to new therapies.

Mesa Biotech, Inc. is a company focused on designing, developing, and manufacturing molecular diagnostic tests for infectious diseases. Founded in 2015 and based in San Diego, California, with a satellite laboratory in Santa Fe, New Mexico, Mesa Biotech has created a range of products, including the Accula Dock and various Accula test cassettes for influenza and respiratory syncytial virus. The company utilizes innovative technology that simplifies DNA and RNA testing, combining the convenience of rapid point-of-care tests with the sensitivity and specificity typically associated with laboratory-based molecular diagnostics. This approach allows healthcare professionals to obtain actionable, laboratory-quality results quickly and efficiently.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.